These results support our finding of pathological angiogenesis, since it is expected that, when treated with IFN-β, junction cells are more metabolically active, given that this is where new tube formation is initiated.Of special interest, we showed that SLE serum is also able to reduce the angiogenic capacity of endothelial cells. Here, IFNB1 is linked to systemic lupus erythematosus.